Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-26 @ 12:24 AM
NCT ID:
NCT02805660
Group ID:
EG006
Title:
Phase 2: Combination Regimen - Cohort 4
Description:
Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent who had progression of disease ≤ 16 weeks after initiation of treatment were included in this cohort.
Durvalumab - 1500 mg: Participants received durvalumab as an intravenous infusion every 4 weeks.
Mocetinostat - Recommended Phase 2 Dose (70 mg): Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
Deaths Number Affected:
12
Deaths Number At Risk:
None
Serious Number Affected:
11
Serious Number At Risk:
19
Other Number Affected:
18
Other Number At Risk:
19
Study:
NCT02805660
Results Section:
NCT02805660
Adverse Events Module:
NCT02805660